NCT04590183

The Effectiveness and Safety of FK-506 for the Treatment of Posner-Schlossman Syndrome

Peking University Third Hospital Medical Science Research Ethics Committee

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the effectiveness and safety of tacrolimus eye drops (FK-506) in the treatment of Posner-Schlossman Syndrome. It is expected to collect 30 patients with PSS who are in the Ophthalmology Department of Peking University Third Hospital. The included PSS patients were divided into experimental group and control group using simple randomization method. Among them, the experimental group was treated with FK-506 twice a day, and the control group was treated with prednisolone acetate ophthalmic suspension 1% 4 times a day. For all PSS patients whose intraocular pressure is higher than 30mmHg, also add brinzolamide eye drops 3 times a day. Best corrected visual acuity, Goldmann intraocular pressure, anterior section photographs, corneal endothelial cells，corneal confocal microscope, Heidelberg retinal nerve analysis, Octopus visual field were examined on baseline and 1 week, 2 weeks, 3 weeks, 4 weeks after the treatment.

Conditions

• Posner Schlossman Syndrome

Interventions

Type	Name	Description
DRUG	FK-506 (Drug)	Twice a day
DRUG	Prednisolone Acetate 1% Oph Susp	Four times a day

Timeline

• Start date: 2020-10-01
• Primary completion: 2021-08-01
• Completion: 2021-09-01
• First posted: 2020-10-19
• Last updated: 2021-08-16

Locations

1 site across 1 country: China